Vericel (VCEL) is a commercial-stage biopharma company that focuses on sports medicine and severe burn care therapies. President and CEO, Nick Colangelo discusses VCEL as it expects an accelerated commercial launch for arthroscopic Maci. he notes that VCEL anticipates an accelerated potential commercial launch of arthroscopic Maci in 2024. He then goes over how VCEL announced FDA approval of Nexobird, U.S. commercial availability expected in 2Q23. Tune in to find out more about the stock market today.
The Watch List
20 Jan 2023
SHARE
Morning Trade Live
06 Dec 2023
Market On Close
24 Oct 2023
Morning Trade Live
08 Dec 2023
Morning Trade Live
09 Jan 2024
Trading 360
03 Jan 2024
Trading 360
04 Jan 2024